China's NMPA has deeply integrated with global regulatory frameworks — IMDRF, ISO/IEC, and UDI — faster than most foreign manufacturers realize. China has implemented 33 of 36 IMDRF technical documents, adopted Essential Principles equivalent to the EU MDR's GSPR, embedded the international eRPS dossier structure into its submission system, and is actively expanding acceptance of multi-regional clinical trial data. For foreign manufacturers, this convergence meaningfully reduces the gap between an existing CE or FDA dossier and what NMPA requires — if you know where to leverage it.
The narrative that China's regulatory system is uniquely opaque and disconnected from international norms is increasingly outdated. Since joining IMDRF in 2013, China has moved from a follower to a leader in global medical device regulatory harmonization — serving as IMDRF chair, leading the clinical evaluation working group, and driving the adoption of international standards at a pace that now exceeds 90% alignment.
For foreign manufacturers approaching NMPA registration, understanding this convergence is not just background knowledge — it directly affects how you structure your dossier, what clinical evidence you can use, and how much of your existing regulatory work translates across markets.
1. The Policy Foundation: State Council Reform Document No. 53
The 2024 State Council reform document (国办发〔2024〕53号) sets the explicit policy direction for China's regulatory internationalization. Three articles are directly relevant to foreign manufacturers:
| Article | Provision | Practical Implication |
|---|---|---|
| Article 18 | Actively promote implementation of IMDRF and GHWP technical guidelines in China. Support international multi-center clinical trials and promote simultaneous global development, submission, review, and approval. | IMDRF-compliant documentation increasingly applicable in China; MRCT data pathway actively supported |
| Article 19 | Encourage international exchange and regulatory cooperation. Support medical device enterprises in developing international markets. Encourage third-party service ecosystems for export. | Policy support for both inbound registration and outbound market development |
| Article 21 | Expand export sales certificate scope to all qualified enterprises manufacturing under GMP standards. | Streamlined export documentation for Chinese manufacturers going global |
These provisions are not aspirational — they are being implemented through concrete regulatory actions across NMPA's technical review, standards, and submission systems.
2. IMDRF: China as a Full Member and Active Leader
China joined IMDRF (International Medical Device Regulators Forum) in 2013 and has since become one of its most active members. The key facts foreign manufacturers need to understand:
- Full member status — China is one of 10 IMDRF member nations, with regulatory officials on the Management Committee
- IMDRF chair, 2018 — China hosted and chaired the 13th and 14th Management Committee meetings
- Leading the clinical evaluation working group — China led the drafting of four foundational IMDRF clinical guidance documents: Clinical Evidence (Key Definitions and Concepts), Clinical Evaluation, Clinical Investigation, and Post-Market Clinical Follow-up Study
- 33 of 36 implemented — Of all IMDRF technical documents published to date, China has fully or partially implemented 33
IMDRF guidance documents form the technical backbone of both EU MDR and US FDA regulatory frameworks. Because NMPA has implemented the same underlying IMDRF documents, the structure and content expectations for clinical evaluation, risk management, and essential principles are substantively aligned across these three major markets. A well-constructed EU MDR technical file is a much stronger starting point for an NMPA dossier than it was five years ago.
3. eRPS: One Dossier Structure for Multiple Markets
The electronic Regulated Product Submission (eRPS) is an IMDRF initiative to standardize how regulatory dossiers are organized and submitted globally. The eRPS Table of Contents (ToC) provides a universal framework for structuring registration documentation.
China's NMPA has embedded the eRPS ToC structure directly into its electronic submission system. This is a significant practical development:
- Dossiers prepared according to eRPS ToC format are directly compatible with NMPA's submission portal
- Manufacturers no longer need to completely restructure their documentation for the Chinese market if it was originally organized per eRPS ToC
- Canada's Health Canada — the IMDRF RPS working group lead — adopted "Non-eCTD Electronic-Only" format in 2017; NMPA's adoption aligns China with this international standard
The long-term vision articulated by NMPA's Center for Medical Device Evaluation: a single registration submission package in eRPS format could support registration applications across multiple regulatory jurisdictions simultaneously. This is not yet reality, but the infrastructure is being built.
4. Essential Principles: The Direct Link to EU MDR's GSPR
China's Essential Principles for Safety and Performance (医疗器械安全和性能基本原则, ESPP) are directly equivalent to the IMDRF 2018 Essential Principles document — which is the same framework that underpins the EU MDR's General Safety and Performance Requirements (GSPR, Annex I).
How Essential Principles Work in NMPA Registration
An Essential Principles (EP) Checklist must be included as a required component of NMPA registration dossiers. The EP Checklist:
- Lists each applicable safety and performance requirement from the Essential Principles
- Maps each requirement to the corresponding conformance evidence in the dossier
- Provides a closed-loop from "requirement stated" to "requirement demonstrated"
- Forms the systematic evaluation framework that NMPA reviewers use to assess completeness
For devices with special characteristics, the Essential Principles include specific requirements for absorbable devices, radiation-emitting devices, implants, and drug-containing devices.
Manufacturers with existing EU MDR GSPR checklists have a direct head start on the NMPA EP Checklist. The structure is equivalent; the mapping exercise involves identifying Chinese standard equivalents for the conformance evidence, but the framework is the same.
5. UDI: China's Three-Phase Implementation
The Unique Device Identification (UDI) system has become the universal language of global medical device traceability. IMDRF's predecessor (GHTF) established UDI principles in 2008; China has been implementing UDI in phases since then.
China's Current UDI Scope
As of the current implementation stage, UDI labeling and database registration is mandatory for:
- All Class III devices — the highest risk tier
- 15 categories of Class II devices — covering 103 specific product types
UDI Structure in China
China's UDI system follows the international standard: UDI = DI (Device Identifier) + PI (Production Identifier)
- DI (Device Identifier) — identifies the specific version/model; remains constant for a given device version
- PI (Production Identifier) — identifies the specific production unit: lot/batch number, serial number, manufacturing date, expiry date as applicable
UDI has become the "passport" for medical devices in global trade — increasingly required not just for China but for all major markets simultaneously. NMPA requires foreign manufacturers to obtain a UDI issuing agency code, label devices with UDI, and register in China's national UDI database before market entry for covered products. Foreign manufacturers already UDI-labeled for FDA or EU MDR compliance can leverage existing labels — but must verify the issuing agency is recognized in China and complete NMPA database registration.
6. Multi-Regional Clinical Trials (MRCT)
China's acceptance of international multi-regional clinical trial (MRCT) data is expanding significantly. The 2024 State Council reform document explicitly supports simultaneous global development, submission, and review — a structural shift from the historical requirement for China-specific clinical data.
Why MRCTs Matter for Device Registration
- Recruitment scale — MRCTs solve the challenge of recruiting sufficient patients for rare disease or specialized device indications
- Data diversity — Multinational data increases generalizability and often strengthens the clinical evidence package for NMPA review
- Simultaneous timelines — Designing a clinical study as MRCT from the outset enables parallel submissions to NMPA, FDA, and notified bodies, compressing global market access timelines
NMPA's expanding MRCT acceptance doesn't eliminate the need for clinical data — it changes where that data can be collected. For Class III devices with novel indications, an MRCT designed to include Chinese sites and Chinese patient data is now the preferred pathway over separate China-only studies.
7. International Standards: 90%+ Alignment and Growing
China's medical device standards have converged substantially with ISO and IEC international standards:
| Year | Standards adopting international equivalents | New international standard conversions approved |
|---|---|---|
| 2022 | — | 117 conversion applications submitted (2× the 2020 figure) |
| 2023 | 66 national/industry standards | 86 international-to-China conversions approved |
| 2024 | 71 national/industry standards | 45 international-to-China conversions approved |
Overall alignment between Chinese medical device standards and international standards now exceeds 90%. China has also moved from standard-adopter to standard-setter: Chinese experts now chair IEC SC 62B and serve as IEC TC62 Vice-Chair, with 144 registered experts in ISO/IEC working groups. China has led the development of multiple international standards including those for surgical instruments, infusion devices, IVD nucleic acid testing, and AI/ML-based medical devices.
8. What This Means for Your Registration Strategy
Leverage Your Existing Documentation More Aggressively
If your device has CE marking under MDR, your technical documentation already covers most of what NMPA requires at the framework level. The key work is:
- Reorganizing per eRPS ToC (often minor if already well-structured)
- Replacing EU/US standard citations with Chinese GB/YY equivalents (most map 1:1)
- Completing the EP Checklist (directly analogous to your MDR GSPR checklist)
- Conducting China laboratory testing for mandatory in-China tests (still required)
Design Clinical Strategies Globally
For Class III devices in development, design your clinical strategy as MRCT from the outset. Including Chinese sites in an MRCT from day one is more efficient than conducting a separate China study after FDA/CE approval.
Implement UDI Early
If your device is in the UDI scope, implement it before starting the registration process — not after. UDI information must be consistent with labeling submitted in the registration dossier, and changes post-registration require amendment notifications.
Watch the Standards Pipeline
With 45–86 new international standard conversions approved annually, the standards landscape is shifting faster than most compliance teams track. A standard that was China-specific two years ago may now have an international equivalent — and vice versa, an international standard may now have been superseded by a newer Chinese version with additional requirements.